Program
CTO0307
A development code. Also written as “CTO0307 Eye drop”.
Its studies are mostly in Presbyopia, led by Taejoon Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Taejoon Pharmaceutical | 10 open or running | phase 3since Jul 19, 2026 | Jul 19, 2026 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 19, 2026First study: phase 3 study in PresbyopiaFirst studyNCT07723716 · 167 enrolled · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07723716Presbyopia · South Korea | 3 | Completed | Sep 25, 2025 | 167 |
How it is read
Names in the registry
- “CTO0307 Eye drop”, 1 entry
Codes read as this program: CTO0307.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.